Clinical Trials · NCT05963022
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 206
- Start date
- Aug 2023
- Locations
- 28 sites, China
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)